Antibody-initiated beneficial and harmful immune responses

  • Arpad Zsigmond Barabas
  • Chad Douglas Cole
  • Rene Lafreniere


A critical function of the immune system is to maintain tolerance to self by corrective immune responses throughout life, including preventing or correcting changes that may interfere with organ function and architectural integrity. These changes have two broad categories, namely (1) exogenous antigen-induced mishaps (e.g., due to bacterial, viral or fungal infections) and (2) endogenous antigen-caused ailments initiated by modified self-antigens derived from damaged organs following exposure to smoke, certain drugs, chemicals, infectious agents, radiation, etc., resulting in autoimmune diseases or cancer. In some cases, cells of the immune system are unable to respond with a corrective antibody response. For example, presentation of a modified self-antigen can initiate a pathogenic IgG immune response, thereby causing an autoimmune disease. Furthermore, if cancer-associated antigens are not appropriately presented to the cells of the immune system, there is failure to mount a specific pathogenic lytic IgG autoantibody response for recognition and elimination of cancer-associated antigens, and as a consequence, the cancer continues to proliferate.

The third vaccination technique that we have developed and designated a modified vaccination technique (MVT) is able to correct these immunological mishaps. The premise of the MVT is that it can prevent both exogenous (infectious and contagious diseases) and endogenous (autoimmune diseases and cancer) antigen-caused diseases, as well as terminate established diseases. Therefore, by exploiting the immune system’s natural abilities to make corrective responses, it has both prophylactic and therapeutic actions, with minimal side effects.


Antibody-initiated beneficial Harmful immune responses 









Brush border


Heymann nephritis


Immune complex


Immune complex glomerulonephritis


Multiple myeloma


Modified vaccination technique


Slowly progressive Heymann nephritis


Molecular weight



We acknowledge the assistance of our research associate, Zoltan Kovacs, in computer and laboratory-related work.

Compliance of ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.


  1. 1.
    Avrameas S. Natural autoantibodies: from ‘horror autotoxicus’ to ‘gnothi seauton’. Immunol Today. 1991;12(5):154–9.PubMedGoogle Scholar
  2. 2.
    Barabas AZ, Cole CD, Barabas AD, Lafreniere R. Down-regulation of pathogenic autoantibody response in a slowly progressive Heymann nephritis kidney disease model. Int J Exp Pathol. 2004;85(6):321–34.CrossRefGoogle Scholar
  3. 3.
    Barabas AZ, Cole CD, Barabas AD, Lafreniere R. Production of Heymann nephritis by a chemically modified renal antigen. Int J Exp Pathol. 2004;85(5):277–85.CrossRefGoogle Scholar
  4. 4.
    Barabas AZ, Lafreniere R. Antigen-specific down-regulation of immunopathological events in an experimental autoimmune kidney disease. Autoimmun Rev. 2005;4(8):565–70.CrossRefGoogle Scholar
  5. 5.
    Boes M, Schmidt T, Linkemann K, Beaudette BC, Marshak-Rothstein A, Chen J. Accelerated development of IgG autoantibodies and autoimmune disease in the absence of secreted IgM. Proc. Natl. Acad. Sci. U. S A. 2000;97(3):1184–9.CrossRefGoogle Scholar
  6. 6.
    Ogden CA, Kowalewski R, Peng Y, Montenegro V, Elkon KB. IgM is required for efficient complement mediated phagocytosis of apoptotic cells in vivo. Autoimmunity. 2005;38(4):259–64.CrossRefGoogle Scholar
  7. 7.
    Quartier P, Potter PK, Ehrenstein MR, Walport MJ, Botto M. Predominant role of IgM-dependent activation of the classical pathway in the clearance of dying cells by murine bone marrow-derived macrophages in vitro. Eur J Immunol. 2005;35(1):252–60.CrossRefGoogle Scholar
  8. 8.
    Barabas AZ, Cole CD, Weir DM & Lafreniere R. (2011) Immunopathological events in an experimental autoimmune kidney disease and how those events can be terminated to regain tolerance to self. In Autoimmune disorders: symptoms, diagnosis and treatment. Petrov M, editor. Hauppauge: Nova Science Publishers, Inc. 35–66.Google Scholar
  9. 9.
    Barabas AZ, Cole CD, Barabas AD, Barabas AN, Lafreniere R. Reduced incidence of slowly progressive Heymann nephritis in rats immunized with a modified vaccination technique. Clin Dev Immunol. 2006;13(1):17–24.CrossRefGoogle Scholar
  10. 10.
    Barabas AZ, Cole CD, Barabas AD, Lafreniere R. Downregulation of a pathogenic autoantibody response by IgM autoantibodies directed against the nephritogenic antigen in slowly progressive Heymann nephritis. Pathol Int. 2006;56(4):181–90.CrossRefGoogle Scholar
  11. 11.
    Barabas AZ, Cole CD, Kovacs ZB, Lafreniere R. Elevated antibody response by antigen presentation in immune complexes. Med Sci Monit. 2007;13(5):BR119–24.PubMedGoogle Scholar
  12. 12.
    Barabas AZ, Cole CD, Barabas AD, Lafreniere R. Preventative and therapeutic vaccination to combat an experimental autoimmune kidney disease. Biologics. 2007;1(1):59–68.PubMedPubMedCentralGoogle Scholar
  13. 13.
    Barabas AZ, Weir DM, Cole CD, Barabas AD, Bahlis NJ, Graeff RM, et al. Preventing and treating chronic disorders using the modified vaccination technique. Front Biosci. 2009:143892–8.Google Scholar
  14. 14.
    Barabas AZ, Cole CD, Graeff RM, Lafreniere R, Weir DM. Tolerance, loss of tolerance and regaining tolerance to self by immune-mediated events. Immunol Res. 2017;65(1):402–9.CrossRefGoogle Scholar
  15. 15.
    Barabas AZ, Cole CD, Barabas AD, Bahlis NJ, Lafreniere R. A vaccination technique to combat presently untreatable chronic ailments. Bioprocess J. 2007;6(4):12–8.CrossRefGoogle Scholar
  16. 16.
    Heymann W. Experimental analogues of human nephropathies. In: International Proc. 3rd Int. Congr. Nephrol. New York: Karger, Basel; 1967. p. 164–77.Google Scholar
  17. 17.
    Barabas AZ, Cole CD, Barabas AD, Lafreniere R. Production of a new model of slowly progressive Heymann nephritis. Int J Exp Pathol. 2003;84(6):245–58.CrossRefGoogle Scholar
  18. 18.
    Weir DM, Pinckard RN, Elson CJ, Suckling DE. Naturally occurring anti-tissue antibodies in rat sera. Clin Exp Immunol. 1966;1(4):433–42.PubMedPubMedCentralGoogle Scholar
  19. 19.
    Weir DM, Pinckard RN. Failure to induce tolerance to rat tissue antigens. Immunology. 1967;13(4):373–80.PubMedPubMedCentralGoogle Scholar
  20. 20.
    Manson JJ, Mauri C, Ehrenstein MR. Natural serum IgM maintains immunological homeostasis and prevents autoimmunity. Springer Semin Immunopathol. 2005;26(4):425–32.CrossRefGoogle Scholar
  21. 21.
    Barabas AZ, Cole CD, Graeff RM, Morcol T, Lafreniere R. A novel modified vaccination technique produces IgG antibodies that cause complement-mediated lysis of multiple myeloma cells carrying CD38 antigen. Human Antibodies. 2017;24(3–4):45–51.CrossRefGoogle Scholar
  22. 22.
    Zwart B, Ciurana C, Rensink I, Manoe R, Hack CE, Aarden LA. Complement activation by apoptotic cells occurs predominantly via IgM and is limited to late apoptotic (secondary necrotic) cells. Autoimmunity. 2004;37(2):95–102.CrossRefGoogle Scholar
  23. 23.
    Barabas AZ, Cole CD, Barabas AD, Barabas AN, Lafreniere R. Effect of rat kidney fraction 3 (rKF3) antigen and specific IgM antibody against rKF3 on the progression of slowly progressive Heymann nephritis. Pathol Int. 2006;56(9):516–29.CrossRefGoogle Scholar
  24. 24.
    Hogan SL, Muller KE, Jennette JC, Falk RJ. A review of therapeutic studies of idiopathic membranous glomerulopathy. Am J Kidney Dis. 1995;25(6):862–75.CrossRefGoogle Scholar
  25. 25.
    Perna A, Schieppati A, Zamora J, Giuliano GA, Braun N, Remuzzi G. Immunosuppressive treatment for idiopathic membranous nephropathy: a systematic review. Am J Kidney Dis. 2004;44(3):385–401.CrossRefGoogle Scholar
  26. 26.
    Heymann W, Hackel DB, Harwood S, Wilson SG, Hunter JLP. Production of nephritic syndrome in rats by Freund’s adjuvant and rat kidney suspensions. Proc Soc Exp Biol Med. 1959:100660–4.Google Scholar
  27. 27.
    Barabas AZ, Cole CD, Barabas AD, Lafreniere R & Weir DM. (2011) Four aspects of autoimmunity and how to regain tolerance to self from an autoimmune disease utilizing the modified vaccination technique. In Autoimmune disorders - current concepts and advances from bedside to mechanistic insights. Huang FP, editor. Rijeka, Croatia: InTech 569–590.Google Scholar
  28. 28.
    Blank M, Shoenfeld Y. B cell targeted therapy in autoimmunity. J Autoimmun. 2007;28(2–3):62–8.CrossRefGoogle Scholar
  29. 29.
    Lokhorst HM, Plesner T, Laubach JP, Nahi H, Gimsing P, Hansson M, et al. Targeting CD38 with daratumumab monotherapy in multiple myeloma. N Engl J Med. 2015;373(13):1207–19.CrossRefGoogle Scholar
  30. 30.
    McKeage K. Daratumumab: first global approval. Drugs. 2016;76(2):275–81.CrossRefGoogle Scholar
  31. 31.
    Nahta R, Esteva FJ. Trastuzumab: triumphs and tribulations. Oncogene. 2007;26(25):3637–43.CrossRefGoogle Scholar
  32. 32.
    Rommer PS, Dudesek A, Stuve O, Zettl UK. Monoclonal antibodies in treatment of multiple sclerosis. Clin Exp Immunol. 2014;175(3):373–84.CrossRefGoogle Scholar
  33. 33.
    Andreakos E, Taylor PC, Feldmann M. Monoclonal antibodies in immune and inflammatory diseases. Curr Opin Biotechnol. 2002;13(6):615–20.CrossRefGoogle Scholar
  34. 34.
    Becker BN, Fuchs H, Hakim R. Intravenous immune globulin in the treatment of patients with systemic lupus erythematosus and end-stage renal disease. J Am Soc Nephrol. 1995;5(10):1746–50.PubMedGoogle Scholar
  35. 35.
    Feldmann M, Steinman L. Design of effective immunotherapy for human autoimmunity. Nature. 2005;435(7042):612–9.CrossRefGoogle Scholar
  36. 36.
    Leandro MJ, Edwards JC, Cambridge G, Ehrenstein MR, Isenberg DA. An open study of B lymphocyte depletion in systemic lupus erythematosus. Arthritis Rheum. 2002;46(10):2673–7.CrossRefGoogle Scholar
  37. 37.
    Mok CC. Rituximab for the treatment of rheumatoid arthritis: an update. Drug Des Devel Ther. 2013:887–100.Google Scholar
  38. 38.
    Townsend MJ, Monroe JG, Chan AC. B-cell targeted therapies in human autoimmune diseases: an updated perspective. Immunol Rev. 2010;237(1):264–83.CrossRefGoogle Scholar
  39. 39.
    Barabas AZ, Cole CD, Lafreniere R, Weir DM. Regaining tolerance to a self-antigen by the modified vaccination technique. Clin Rev Allergy Immunol. 2013;45(2):193–201.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  • Arpad Zsigmond Barabas
    • 1
  • Chad Douglas Cole
    • 2
  • Rene Lafreniere
    • 1
  1. 1.Department of SurgeryUniversity of CalgaryAlbertaCanada
  2. 2.Department of NeurosurgeryUniversity of UtahSalt Lake CityUSA

Personalised recommendations